Immix Biopharma Inc Dossier
Qualitative Analysis
Business overview
Immix Biopharma, Inc. (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company pioneering tissue-specific therapeutics and chimeric antigen receptor cell therapies (CAR-T). The company's primary value driver is NXC-201, a next-generation, sterically-optimized CAR-T cell therapy targeting B-cell maturation antigen (BCMA). NXC-201 is currently being evaluated in the U.S. Phase 1b/2 NEXICART-2 clinical trial and ex-U.S. Phase 1b/2a NEXICART-1 clinical trial for relapsed/refractory light chain (AL) Amyloidosis and other serious diseases. NXC-201 has received FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug Designations. Additionally, the company is developing IMX-110, a first-in-class tissue-specific multi-kinase inhibitor targeting solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the clinical advancement of lead CAR-T candidate NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. The company completed patient enrollment for its BLA-enabling NEXICART-2 trial in March 2026.
Expected impact: Establish NXC-201 as the first FDA-approved disease-modifying cell therapy for relapsed/refractory AL Amyloidosis.
Expanding the therapeutic footprint of NXC-201 beyond AL Amyloidosis into other serious immune-mediated and autoimmune diseases where BCMA-targeted CAR-T therapies show clinical promise.
Expected impact: Broaden the addressable market size and maximize the commercial value of the NXC-201 asset.
Actively seeking strategic partnerships to out-license NXC-201 for indications outside of its core focus of AL Amyloidosis, allowing the company to retain core rights while leveraging partner resources.
Expected impact: Generate non-dilutive upfront and milestone-based funding to support core clinical trials and commercial preparation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Immix Biopharma absorbed its majority-owned subsidiary Nexcella, Inc. via a short-form merger. This transaction consolidated 100% ownership of Nexcella's assets, operations, and intellectual property rights—most notably the lead CAR-T cell therapy candidate NXC-201—directly into Immix Biopharma, simplifying the corporate structure and eliminating minority interest overhead.
Financial impact: Immix issued 989,876 shares of its common stock to former minority stockholders of Nexcella and assumed all of Nexcella's rights and obligations, including the core IP license agreement with Hadasit and BIRAD.
Strategic Partnerships
Provides Immix Biopharma (originally through Nexcella) with the exclusive global license to develop, manufacture, and commercialize the BCMA-targeted CAR-T cell therapy NXC-201.
Terms: Includes an upfront license fee, annual license fees, and a requirement to pay royalties of 5% on net sales of licensed products during the royalty period.
Collaborative clinical study evaluating the safety, tolerability, and efficacy of combining Immix's tissue-specific therapeutic IMX-110 with BeiGene's anti-PD-1 antibody tislelizumab in patients with advanced solid tumors.
Terms: Immix sponsors and manages the clinical trial, covering all operational costs, while BeiGene provides its clinical-grade tislelizumab product at its own expense.